Benjamin Richard J 4

What Happened Benjamin Richard J, Chief Medical Officer of Cerus Corp (CERS), reported an award and multiple open‑market sales in early March 2026. On 2026-03-05 he received 55,220 shares (award/acquisition at $0.00), and he sold a total of 125,894 shares across three sales: 61,233 shares on 2026-03-05 at $2.06 ($126,305), 24,235 shares on 2026-03-06 at $2.01 ($48,603), and 40,426 shares on 2026-03-09 at $1.88 ($76,029). Total reported proceeds from the sales were about $250,937. The filing notes that some sales were to cover statutory tax withholding in connection with RSU vesting.

Key Details

• Dates & prices:
  • 2026-03-05: Award of 55,220 shares at $0.00 (acquisition).
  • 2026-03-05: Sold 61,233 shares @ $2.06 — $126,305.
  • 2026-03-06: Sold 24,235 shares @ $2.01 — $48,603.
  • 2026-03-09: Sold 40,426 shares @ $1.88 — $76,029.
• Total sold: 125,894 shares for ~ $250,937; total acquired via award: 55,220 shares.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes of note:
  • F1: Some shares were sold pursuant to a Rule 10b5-1 instruction to cover statutory tax withholding and brokerage fees related to RSU vesting — described as not a discretionary sale.
  • F2–F4: Sales include weighted‑average pricing, a block trade, and sales in price ranges; the reporting person offers to provide full breakdowns on request.
• Timeliness: Form 4 filed 2026-03-09 for transactions dated 2026-03-05 through 2026-03-09 — filing appears timely (no late filing indicated).

Context

• These transactions combine an RSU vesting (award) and subsequent open‑market sales, at least some of which were executed to satisfy tax withholding — a common, routine insider action. There were no reported purchases in this filing; sales do not necessarily indicate negative company outlook and, per the filing, include non‑discretionary tax‑related sales under a 10b5-1 plan.